3 Year Results of Tacrolimus in Kidney Transplantation: Single Center Experience / 대한이식학회지
The Journal of the Korean Society for Transplantation
;
: 31-36, 2004.
Article
in Korean
| WPRIM
| ID: wpr-227337
ABSTRACT
PURPOSE:
Results of the US randomized, comparative, multicenter study demonstrated that tacrolimus (Tac) was equivalent to cyclosporine (CyA) in 1-year patient and graft survival in recipients of cadaveric renal transplants. However, the incidence and severity of acute rejection was significantly lower in Tac-treated patients compared with CyA-treated patients. This retrospective, non-randomized single center study represents results of follow-up to 3 years posttransplant.METHODS:
A total of 97 kidney transplant recipients were included; 41 received Tac-based immunosuppression, and 56 received CyA-based immunosuppression and followed for 3 years posttransplant. Serious adverse events were also monitored over 3 years.RESULTS:
The three-year patient survival rates were 95.0% and 96.5% for Tac and CyA, respectively (P=NS). Corresponding graft survival rates were 90.2% and 91.0%, respectively (P=NS). However, the incidence of acute rejection was significantly less in the Tac-group compared with the CyA-group (17.1% vs. 35.7%, P=0.043). The rate of crossover was significantly higher in the CyA-group (4.9% vs. 21.4%, P=0.013). Renal function at 3 years was similar in both treatment groups. The incidence of posttransplant diabetes mellitus (PTDM), head-ache and alopecia was significantly less in the CyA-group, and that of hypertension, hypercholesterolemia after transplantation was significantly less in Tac-group. The incidence of hirsutism and gingival hyperplasia was negligible in Tac-group. Incidence of hand tremor, hyperkalemia, bacterial and viral infection, and malignancy was comparable in both groups. The incidence of PTDM was significantly less in CyA-group (26.8% vs. 7.1%, P=0.008). Nine (81.8%) of the 11 Tac patients with PTDM were off of insulin at 3 years.CONCLUSIONS:
Tacrolimus is a very effective primary immunosuppressive agent in renal transplant recipient. The reduced incidence of acute rejection along with decreased incidence of hypertension and hyperlipidemia after transplantation suggests potential long-term advantage with the use of this drug.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Transplantation
/
Tremor
/
Cadaver
/
Incidence
/
Survival Rate
/
Retrospective Studies
/
Follow-Up Studies
/
Immunosuppression Therapy
/
Kidney Transplantation
/
Tacrolimus
Type of study:
Incidence study
/
Observational study
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
Korean
Journal:
The Journal of the Korean Society for Transplantation
Year:
2004
Type:
Article
Similar
MEDLINE
...
LILACS
LIS